UPDATE: Credit Suisse Downgrades Infinity Pharmaceuticals on Limited Clinical News in 2014
December 12, 2013 at 09:02 AM EST
In a report published Thursday, Credit Suisse analyst Jason Kantor downgraded the rating on Infinity Pharmaceuticals (NASDAQ: INFI ) from Outperform to Neutral, but reiterated the $20.00 price target. In the report, Credit Suisse noted, “We are downgrading INFI to Neutral because (1) limited clinical data is expected in 2014,